1 recruiting, 1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Peptide Receptor Radionuclide Therapy: new trials by email Literature Review of Peptide Receptor Radionuclide Therapy trials Research Report on Peptide Receptor Radionuclide Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors Peptide Receptor Radionuclide Therapy - Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor | Recruiting | Methodist Health System | 50 | 2024-03-28 | 2026-03-20 | |
| Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo - Neuroendocrine Tumors, Carcinoid Syndrome | Phase 2 | Withdrawn | Chandrikha Chandrasekhara | 2021-03-03 | 2023-02-10 |
Neuroendocrine Tumors (2) · Diarrhea (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Serotonin Syndrome (1)
Chandrikha Chandrasekhara (1) · Methodist Health System (1)
United States (2)
Al B Benson, MD (1) · Alejandro Mejia, MD (1) · Chandrikha Chandrasekharan, MD (1)